These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28365442)

  • 21. Molecular mechanisms of the juvenile form of Batten disease: important role of MAPK signaling pathways (ERK1/ERK2, JNK and p38) in pathogenesis of the malady.
    Shematorova EK; Shpakovski DG; Chernysheva AD; Shpakovski GV
    Biol Direct; 2018 Sep; 13(1):19. PubMed ID: 30621751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CLN3, at the crossroads of endocytic trafficking.
    Cotman SL; Lefrancois S
    Neurosci Lett; 2021 Sep; 762():136117. PubMed ID: 34274435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. btn1, the Schizosaccharomyces pombe homologue of the human Batten disease gene CLN3, regulates vacuole homeostasis.
    Gachet Y; Codlin S; Hyams JS; Mole SE
    J Cell Sci; 2005 Dec; 118(Pt 23):5525-36. PubMed ID: 16291725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mfsd8 localizes to endocytic compartments and influences the secretion of Cln5 and cathepsin D in Dictyostelium.
    Huber RJ; Mathavarajah S; Yap SQ
    Cell Signal; 2020 Jun; 70():109572. PubMed ID: 32087303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).
    Seigel GM; Lotery A; Kummer A; Bernard DJ; Greene ND; Turmaine M; Derksen T; Nussbaum RL; Davidson B; Wagner J; Mitchison HM
    Mol Cell Neurosci; 2002 Apr; 19(4):515-27. PubMed ID: 11988019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Batten disease gene CLN3 confers resistance to endoplasmic reticulum stress induced by tunicamycin.
    Wu D; Liu J; Wu B; Tu B; Zhu W; Luo J
    Biochem Biophys Res Commun; 2014 Apr; 447(1):115-20. PubMed ID: 24699413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel CLN3 mutation predicted to cause complete loss of protein function does not modify the classical JNCL phenotype.
    Kwon JM; Rothberg PG; Leman AR; Weimer JM; Mink JW; Pearce DA
    Neurosci Lett; 2005 Oct; 387(2):111-4. PubMed ID: 16087292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of specificity of antibodies raised against CLN3, the lysosomal/endosomal transmembrane protein mutated in juvenile Batten disease.
    Nelson T; Pearce DA; Kovács AD
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29089465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect.
    de los Reyes E; Dyken PR; Phillips P; Brodsky M; Bates S; Glasier C; Mrak RE
    J Child Neurol; 2004 Jan; 19(1):42-6. PubMed ID: 15032383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coding sequence and exon/intron organization of the canine CLN3 (Batten disease) gene and its exclusion as the locus for ceroid-lipofuscinosis in English setter dogs.
    Shibuya H; Liu PC; Katz ML; Siakotos AN; Nonneman DJ; Johnson GS
    J Neurosci Res; 1998 May; 52(3):268-75. PubMed ID: 9590435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological Effects on Ceroid Lipofuscin and Neuronal Structure in Cln3
    Brenneman DE; Pearce DA; Kovacs A; DeFrees S
    J Mol Neurosci; 2017 Sep; 63(1):100-114. PubMed ID: 28812237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unbiased Cell-based Screening in a Neuronal Cell Model of Batten Disease Highlights an Interaction between Ca2+ Homeostasis, Autophagy, and CLN3 Protein Function.
    Chandrachud U; Walker MW; Simas AM; Heetveld S; Petcherski A; Klein M; Oh H; Wolf P; Zhao WN; Norton S; Haggarty SJ; Lloyd-Evans E; Cotman SL
    J Biol Chem; 2015 Jun; 290(23):14361-80. PubMed ID: 25878248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regional brain atrophy in mouse models of neuronal ceroid lipofuscinosis: a new rostrocaudal perspective.
    Kühl TG; Dihanich S; Wong AM; Cooper JD
    J Child Neurol; 2013 Sep; 28(9):1117-22. PubMed ID: 24014506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X).
    Sarpong A; Schottmann G; Rüther K; Stoltenburg G; Kohlschütter A; Hübner C; Schuelke M
    Clin Genet; 2009 Jul; 76(1):38-45. PubMed ID: 19489875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutated genes in juvenile and variant late infantile neuronal ceroid lipofuscinoses encode lysosomal proteins.
    Vesa J; Peltonen L
    Curr Mol Med; 2002 Aug; 2(5):439-44. PubMed ID: 12125809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of phosphodiesterase-4 inhibitors in juvenile Batten disease (CLN3).
    Aldrich A; Bosch ME; Fallet R; Odvody J; Burkovetskaya M; Rama Rao KV; Cooper JD; Drack AV; Kielian T
    Ann Neurol; 2016 Dec; 80(6):909-923. PubMed ID: 27804148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene symbol: CLN3. Disease: Juvenile neuronal ceroid lipofuscinosis (Batten disease).
    Leman AR; Pearce DA; Rothberg PG
    Hum Genet; 2005 May; 116(6):544. PubMed ID: 15991331
    [No Abstract]   [Full Text] [Related]  

  • 38. Gene symbol: CLN3. Disease: juvenile neuronal ceroid lipofuscinosis (Batten disease).
    Leman AR; Pearce DA; Rothberg PG
    Hum Genet; 2005 Feb; 116(3):236. PubMed ID: 15818814
    [No Abstract]   [Full Text] [Related]  

  • 39. Recent Insights into NCL Protein Function Using the Model Organism
    McLaren MD; Mathavarajah S; Huber RJ
    Cells; 2019 Feb; 8(2):. PubMed ID: 30717401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [From gene to disease; from CLN1, CLN2 and CLN3 to neuronal ceroid lipofuscinosis].
    Taschner PE; Losekoot M; Breuning MH; Hofman I; van Diggelen OP
    Ned Tijdschr Geneeskd; 2005 Feb; 149(6):300-3. PubMed ID: 15730038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.